Medicenna Therapeutics Selects Kalon Biotherapeutics To Manufacture New Cancer Drug - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Medicenna Therapeutics Selects Kalon Biotherapeutics To Manufacture New Cancer Drug


PTSM: Pharmaceutical Technology Sourcing and Management
Volume 10, Issue 7

Medicenna Therapeutics, a clinical stage immune-oncology company, has selected Kalon Biotherapeutics, an advanced biologics contract development and manufacturing company, to manufacture materials that will accelerate the development, testing, and Phase 3/commercialization of several new cancer drugs in the pipeline. The operations of Kalon Biotherapeutics are located in the National Center for Therapeutics Manufacturing on the campus of Texas A&M in College Station, Texas.

Kalon’s first project with Medicenna is for a clinical trial testing the effectiveness of Medicenna’s empowered cytokines (ECs) for children with brain cancer. The agreement provides for Kalon to manufacture the material that will be used in human clinical trials in children and adults with brain cancer.

Source: Kalon Biotherapeutics

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Source: PTSM: Pharmaceutical Technology Sourcing and Management,
Click here